Group 1 - The National Medical Products Administration (NMPA) held a national drug regulation work conference and "Qingyuan" action promotion meeting in Zhengzhou [1] - The meeting emphasized the need to strengthen risk assessment and firmly combat illegal and non-compliant activities [1] - The meeting also highlighted the continuation of information traceability efforts and the enhancement of comprehensive management across all varieties and the entire supply chain [1] - Additionally, the meeting called for the improvement of institutional standards to further guide and regulate drug business activities [1]

Core Viewpoint - The Shaanxi Provincial Drug Administration has released a plan for drug supervision and management for 2025, emphasizing the need to strengthen regulation in key varieties, links, enterprises, and regions to ensure drug quality and safety [1][2] Group 1: Regulatory Actions - Shaanxi will implement the "Qingyuan" action, focusing on drug wholesale and retail enterprises, as well as online sales, to combat illegal drug purchasing and selling channels [1] - The province aims to enhance the traceability system for drug operations, ensuring comprehensive coverage of five categories of drugs through QR code tracking [1] Group 2: Quality Supervision - Increased regulatory efforts will be directed towards vaccines, blood products, and commonly used high-value drugs, with special inspections for traditional Chinese medicine (TCM) products [1] - There will be a focus on prescription drugs and chronic disease medications, particularly in monitoring procurement channels, storage management, and information traceability [1] Group 3: Targeted Inspections - The Shaanxi Provincial Drug Administration will strengthen oversight of illegal sales of TCM formula granules and prescription drugs without proper prescriptions, as well as the absence of licensed pharmacists [2] - Special attention will be given to rural areas and small pharmacies, ensuring they have established quality management systems for drug procurement, acceptance, and storage [2] - Investigations will target issues such as substandard storage conditions and the illegal sale of TCM products, including the sale of inferior or counterfeit goods [2]

Group 1 - The core focus of the news is the "Qingyuan" action initiated by the Tai'an Market Supervision Administration to enhance drug safety and address public concerns regarding drug management [1][2] - The action has been integrated into the annual drug regulation key task list, with a detailed work plan established in collaboration with the municipal administrative approval service bureau [1] - A specialized task force has been formed, consisting of three functional groups: comprehensive, supervision inspection, and case handling, to ensure effective implementation of the action [1] Group 2 - The "Qingyuan" action targets illegal online drug sales, expired and counterfeit drugs, and the unauthorized sale of prescription drugs, focusing on key units and products [2] - Comprehensive inspections are being conducted using on-site checks and online monitoring to effectively combat illegal activities and create a deterrent effect [2] - The Tai'an Market Supervision Administration plans to deepen the "Qingyuan" action by increasing risk assessment efforts and investigating illegal leads to ensure public safety in drug use [2]

Core Viewpoint - The Urumqi Market Supervision Administration is intensifying efforts to regulate the pharmaceutical distribution sector through a "Clean Source" initiative aimed at addressing prominent issues in drug sales and ensuring drug quality safety [1][3][4] Group 1: Regulatory Actions - The administration has mobilized 127 pharmaceutical companies to adhere to principles of "strict prevention at the source, strict management during the process, and strict risk control" [3] - Key focuses include combating illegal drug sales, counterfeit drugs, and violations in online drug sales [3] - Specific measures include enhanced online inspections, strict checks on illegal procurement channels, and increased oversight of high-risk drugs [3] Group 2: Compliance and Training - The administration emphasizes the importance of compliance by requiring pharmaceutical companies to implement full product traceability and rectify identified issues [3][4] - Future plans include ongoing training for pharmacy staff to ensure comprehensive understanding of regulations, thereby safeguarding public health [4]

Core Viewpoint - The National Medical Products Administration (NMPA) has launched a "Clean Source" action to combat illegal activities in the pharmaceutical distribution sector, ensuring public health and safety amid rising issues like counterfeit drugs and illegal online sales [1][2][3]. Group 1: Regulatory Actions - The "Clean Source" action was initiated in April 2023, focusing on eliminating risks and illegal practices in drug distribution, with a commitment to continue until November 2025 [2][5]. - The NMPA has emphasized the importance of cross-departmental collaboration and the use of digital monitoring tools, such as drug traceability codes, to enhance regulatory effectiveness [6][7]. Group 2: Case Examples - Five typical cases of violations were reported, including illegal procurement and sales of drugs, with penalties ranging from fines to the revocation of operating licenses [3][4]. - Specific cases include a pharmacy in Guangdong fined 1.3 million yuan for illegal drug procurement and a pharmacy in Jiangxi penalized for selling drugs without proper qualifications [3][4]. Group 3: Industry Impact - The initiative aims to establish a transparent and compliant pharmaceutical distribution system, promoting industry compliance and enhancing public trust in drug safety [3][6]. - The focus on digital upgrades in drug monitoring is expected to shift regulatory practices from reactive to proactive, improving overall drug safety [6][7].

Core Viewpoint - The Guangzhou Market Supervision Administration has launched a "Clearing Source" action to regulate drug business practices and enhance drug quality supervision across the city [1] Group 1: Action Focus - The action targets issues such as the rental and lending of licenses, production and sale of counterfeit drugs, illegal drug purchases, and the sale of prescription drugs without prescriptions [1] - A leadership team has been established to oversee the "Clearing Source" action, with the Drug and Chemical Department leading the development of the action plan [1] Group 2: Responsibilities and Compliance - The action aims to reinforce the primary responsibility of drug operating enterprises and users, urging them to conduct self-inspections across all drug procurement, sales, storage, and usage stages [1] - Special attention will be given to wholesale enterprises, retail chain headquarters, and retail enterprises that engage in abnormally low-priced drug procurement [1] Group 3: Risk Management and Enforcement - The initiative will strengthen the approval and entry mechanisms, optimize the exit mechanisms, and enhance the management of retail chain enterprises [1] - Comprehensive checks will be conducted on enterprises with a history of complaints, multiple referrals, and inadequate rectifications, including online and offline inspections [1] - The action will involve collaboration with public security, health, and medical insurance departments to thoroughly investigate potential illegal activities and enforce strict penalties for violations [1]